期刊文献+

高浓度胰岛素水平对阿司匹林抑制的血小板聚集率的影响

Effect of High Concentrations of Insulin Levels to Aspirin Inhibits Platelet Aggregation Rate
下载PDF
导出
摘要 目的 研究高浓度的胰岛素是否影响阿司匹林抑制的血小板聚集率.方法 将制备的4组等体积的富含血小板血浆(PRP)分别加入0,30,100和300μU/ml的胰岛素,37℃的环境下孵育3 min,再将上述每一组的PRP分成等体积的4个组,分别加入0,75,150和300 μmol/L的阿司匹林,于37℃的环境下继续孵育30 min.用血小板聚集仪检测各组的血小板最大聚集率.结果 不同浓度胰岛素组之间有显著差异(F=4.056,P=0.008).300 μU/ml胰岛素浓度的富含血小板血浆,在不同浓度阿司匹林0,75,150和300 μmol/L的孵育下,血小板最大聚集率分别为(87.62±6.23)%,(60.85±16.24)%,(55.28±16.48)%和(49.36±16.77)%,均高于相应对照组的血小板最大聚集率(83.82±8.35)%,(48.80±21.35)%,(45.04±21.44)%,(38.90±21.70)%和30 μU/ml胰岛素组的血小板最大聚集率(84.64±8.09)%,(48.13±19.27)%,(44.30±20.50)%和(35.30±16.81)%,其差异有统计学意义(P<0.05);而其他浓度的胰岛素组间比较,差异则无统计学显著性意义.结论 血小板暴露于高浓度的胰岛素(300 μU/ml)环境中,将会减弱阿司匹林对血小板的抗聚集效应. Objective To examine if acute exposure to increased plasma insulin impaired the inhibitory effects of aspirin onplatelet aggregation rete. Methods The equivalent volume of platelet-rich plasma (PRP) prepared by hand was preincubatedwith insulin(0,30,100,300 μU/ml) in 37℃ water for 3 minutes,which was then stimulated with different concentrations ofaspirin (0,75,150,300μmol/L) for 30 minutes in water of 37℃. The platelet maximal aggregation each sample were ana-lyzed by platelet aggregation system. Results There were significant differences between groups with different concentra-tions of insulin (F=-4. 056,P=0. 008). The inhibitory effects of 75,150 and 300 /μmol/I. aspirin differed in the presence of300/iU/ml vs. the absence of insulin (87.62±6.23)%,(60.85±16.24)%,(55.28±16.48)%vs(49.36±16.77)% , whereas they were not significant among other concentrationsof insulin. Conclusion In vitro exposure to high insulin (i. e. ,300 μU/ml) of platelets from healthy subjects reduces the an-tiaggregating action of aspirin.
出处 《现代检验医学杂志》 CAS 2014年第2期97-99,共3页 Journal of Modern Laboratory Medicine
基金 全军十一五计划科技攻关基金资助项日(09BAk61B01).
关键词 胰岛素 阿司匹林 血小板 血小板聚集率 insulin aspirin platelet platelet aggregation rate
  • 相关文献

参考文献16

  • 1Grundy SM,Bilheimer D,Chait A,et al.Summary of the second report of the National Cholesterol Educa-tion Program(NCEP)Expert Panel on Detection,E-valuation,and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅱ)[J].The Jour-nal of the American Medical Association,1993,269(23):3015-3023.
  • 2Vinik A,Erbas T,Park TS,et al.Platelet dysfunction in type 2 diabetes[J].Diabetes Care,2001,24(8)1476-1485.
  • 3Pulcinelli FM,Biasucci LM,Riondino S,et al.COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment[J].Eur Heart J,2009,30(10):1279-1286.
  • 4American Diabetes Association.Standards of medical care in diabetes[J].Diabetes Care,2005,28(suppl 1):S4-S36.
  • 5Ajjan R,Storey RF,Grant PJ.Aspirin resistance and diabetes mellitus[J].Diabetologia,2008,51(3):385-390.
  • 6Angiolillo DJ.Antiplatelet therapy in diabetes:effica-cy and limitations of current treatment strategies andfuture directions[J].Diabetes Care,2009,32(4):531-540.
  • 7De Berardis G,Sacco M,Strippoli GF,et al.Aspirin for primary prevention of cardiovascular events in people with diabetes:meta-analysis of randomised controlled trials [J].BMJ.British Medical Journal,2009,3(39):b4531.
  • 8Patrono C,Rocea B.Aspirin:promise and resistance in the new millennium[J].Arterioscler Thromb Vasc Biol,2008,28(3):s25-s32.
  • 9Anfossi G,Russo I,Trovati M.Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome[J].Curr Vasc Pharmacol,2008,6(4):313-328.
  • 10Sweeny JM,Gorog DA,drug' resistance' FA.Part 1:mechanisms and clinical measurements [J].Nat Rev Cardiol,2009,6(4):273-282.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部